Leerink Swann Research Analysts Lift Earnings Estimates for United Therapeutics Corporation (UTHR)

United Therapeutics Corporation (NASDAQ:UTHR) – Equities researchers at Leerink Swann lifted their Q4 2017 earnings per share estimates for shares of United Therapeutics Corporation in a research report issued to clients and investors on Wednesday. Leerink Swann analyst J. Schwartz now anticipates that the biotechnology company will post earnings of $3.92 per share for the quarter, up from their prior estimate of $3.88.

A number of other equities research analysts also recently issued reports on UTHR. UBS AG reiterated a “sell” rating and issued a $106.00 price objective on shares of United Therapeutics Corporation in a research report on Thursday, July 6th. Zacks Investment Research downgraded United Therapeutics Corporation from a “hold” rating to a “sell” rating in a research report on Thursday, July 13th. ValuEngine upgraded United Therapeutics Corporation from a “buy” rating to a “strong-buy” rating in a research report on Thursday, July 13th. Jefferies Group LLC reiterated a “sell” rating and issued a $105.00 price objective on shares of United Therapeutics Corporation in a research report on Friday, July 14th. Finally, BidaskClub downgraded United Therapeutics Corporation from a “buy” rating to a “hold” rating in a research report on Wednesday, July 19th. Five equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and three have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $132.82.

COPYRIGHT VIOLATION WARNING: This report was first reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this report on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The original version of this report can be viewed at https://sportsperspectives.com/2017/10/27/leerink-swann-research-analysts-lift-earnings-estimates-for-united-therapeutics-corporation-uthr.html.

Shares of United Therapeutics Corporation (UTHR) traded down 1.76% during trading on Thursday, hitting $117.00. The stock had a trading volume of 161,746 shares. The firm’s 50 day moving average is $121.15 and its 200 day moving average is $125.71. United Therapeutics Corporation has a 1-year low of $112.01 and a 1-year high of $169.89. The company has a market cap of $5.08 billion, a PE ratio of 13.57 and a beta of 1.49.

United Therapeutics Corporation (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, October 25th. The biotechnology company reported $6.27 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $4.01 by $2.26. United Therapeutics Corporation had a return on equity of 26.83% and a net margin of 30.50%. The company had revenue of $445.50 million for the quarter, compared to analyst estimates of $426.43 million. During the same quarter last year, the company posted $4.23 EPS. The company’s revenue for the quarter was up 9.1% compared to the same quarter last year.

In other news, Director Christopher Causey sold 580 shares of the firm’s stock in a transaction dated Thursday, September 7th. The stock was sold at an average price of $134.48, for a total transaction of $77,998.40. Following the transaction, the director now directly owns 3,295 shares of the company’s stock, valued at $443,111.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Martine A. Rothblatt sold 2,176 shares of the firm’s stock in a transaction dated Thursday, August 10th. The shares were sold at an average price of $127.11, for a total value of $276,591.36. Following the transaction, the chief executive officer now directly owns 3,245 shares in the company, valued at $412,471.95. The disclosure for this sale can be found here. Insiders have sold 18,368 shares of company stock worth $2,295,419 in the last 90 days. Company insiders own 7.80% of the company’s stock.

Large investors have recently made changes to their positions in the company. State of Wisconsin Investment Board bought a new position in shares of United Therapeutics Corporation during the second quarter valued at about $5,256,000. Comerica Bank grew its stake in shares of United Therapeutics Corporation by 1.3% during the second quarter. Comerica Bank now owns 35,249 shares of the biotechnology company’s stock valued at $4,635,000 after buying an additional 458 shares during the last quarter. River & Mercantile Asset Management LLP bought a new position in shares of United Therapeutics Corporation during the second quarter valued at about $908,000. Sumitomo Mitsui Trust Holdings Inc. grew its stake in shares of United Therapeutics Corporation by 2.3% during the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 123,016 shares of the biotechnology company’s stock valued at $15,959,000 after buying an additional 2,762 shares during the last quarter. Finally, Captrust Financial Advisors bought a new position in shares of United Therapeutics Corporation during the second quarter valued at about $925,000.

About United Therapeutics Corporation

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Earnings History and Estimates for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply